Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill

Executive Summary

US FDA would need additional appropriations to cover all activities contemplated in the legislation – and the bill appears to need a pay-for because it increases the deficit.

Advertisement

Related Content

FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb
Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

Topics

Advertisement
UsernamePublicRestriction

Register

PS120905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel